ERBB2 and gastric cancer: Between 2022 and 2025, its indications were expanded by the FDA to include recurrent HER2+ metastatic breast cancer, HER2-low or HER2-ultralow metastatic breast cancer, and any advanced HER2+ solid tumors (including lung, colorectal, and gastric cancers).12